Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Opus Genetics, Inc.IRD · Entity 5892 | Chief Operating Officer | July 23, 2026 | July 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Opus Genetics, Inc.
Report date July 23, 2026 · Filed July 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 291,440 |
Reported balance
After 2026-07-23 transaction · row 1
1 source rowRow 1 · 2026-07-23 · Sale · Disposed 4,644 · Balance 291,440 F1: The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 23, 2026 Filed Jul 27, 2026 20:07 UTC | Opus Genetics, Inc. IRD · Entity 5892 | SaleCommon Stock | 4,644 | $2.94 | $13,653.36 |
DisclosureSEC source: 0000905148-26-003353 · form4.xml · nonDerivative · entry 1 SCHACHLE JOSEPH K · CIK 0001145914 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291,440 F1 · kind: The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person. Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 20:28 UTC | Opus Genetics, Inc. IRD · Entity 5892 | SaleCommon Stock | 4,697 | $5.22 | $24,519.28 |
DisclosureSEC source: 0000905148-26-001866 · form4.xml · nonDerivative · entry 1 SCHACHLE JOSEPH K · CIK 0001145914 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 296,084 F1 · kind: The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:12 UTC | Opus Genetics, Inc. IRD · Entity 5892 | SaleCommon Stock | 3,719 | $5.25 | $19,525.12 |
DisclosureSEC source: 0000905148-26-001384 · form4.xml · nonDerivative · entry 1 SCHACHLE JOSEPH K · CIK 0001145914 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,781 F1 · kind: The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 22, 2026 Filed Jan 27, 2026 00:50 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-000358 · form4.xml · nonDerivative · entry 1 SCHACHLE JOSEPH K · CIK 0001145914 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 304,500 F1 · shares: Represents a grant of restricted stock units which vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen (16) quarters, subject to the Reporting Person's continuing service. Read SEC document |
| March 13, 2025 Filed Mar 18, 2025 00:56 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 52,500 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000905148-25-000942 · form4.xml · derivative · entry 2 SCHACHLE JOSEPH K · CIK 0001145914 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2035-03-12 F2 · derivative.exercise_date: The option will vest with respect to 25% on March 13, 2026, with the remaining shares vesting quarterly in 12 equal installments thereafter at the end of each quarter, subject to the Reporting Person's continuing service. Read SEC document |
| March 13, 2025 Filed Mar 18, 2025 00:56 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 52,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000942 · form4.xml · nonDerivative · entry 1 SCHACHLE JOSEPH K · CIK 0001145914 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,500 F1 · shares: Represents a grant of restricted stock units which vest in four equal installments on the first, second, third and fourth anniversary of the grant date of March 13, 2025, subject to the Reporting Person's continuing service. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 20:44 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | PurchaseCommon Stock | 2,000 | $2.05 | $4,100.00 |
DisclosureSEC source: 0000905148-24-000999 · form4.xml · nonDerivative · entry 1 SCHACHLE JOSEPH K · CIK 0001145914 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| November 27, 2023 Filed Nov 27, 2023 23:24 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001140361-23-054744 · form4.xml · derivative · entry 1 SCHACHLE JOSEPH K · CIK 0001145914 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2033-11-26 F1 · derivative.exercise_date: The option will vest with respect to 25% on the first anniversary of the grant date, with the remaining shares vesting in equal monthly installments on the last day of each full month over the subsequent 36 months, subject to continuing service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.